122 related articles for article (PubMed ID: 10975384)
21. Clinical experience with 2'-deoxycoformycin.
Catovsky D
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S103-7. PubMed ID: 9137963
[TBL] [Abstract][Full Text] [Related]
22. Lack of significant activity of 2'-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia. A randomized phase II trial from the Childrens Cancer Study Group.
Miser JS; Roloff J; Blatt J; Reaman GH; Krailo MD; Hammond GD
Am J Clin Oncol; 1992 Dec; 15(6):490-3. PubMed ID: 1449110
[TBL] [Abstract][Full Text] [Related]
23. Comparative antineoplastic activity against P388 leukemia of 9-beta-D-arabinofuranosyladenine (araA) and 9-beta-(2'-azido-2'-deoxy-D-arabinofuranosyl) adenine (arazide).
Lee SH; Thomas LK; Unger FM; Christian R; Sartorelli AC
Int J Cancer; 1981 May; 27(5):703-8. PubMed ID: 6974703
[No Abstract] [Full Text] [Related]
24. Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Matsumoto SS; Yu AL; Bleeker LC; Bakay B; Kung FH; Nyhan WL
Blood; 1982 Nov; 60(5):1096-102. PubMed ID: 6289941
[TBL] [Abstract][Full Text] [Related]
25. [Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin].
Nagai T; Izumi T; Noborio K; Takatoku M; Ohtsuki T; Machii T; Komatsu N; Ozawa K
Rinsho Ketsueki; 2002 Jul; 43(7):583-5. PubMed ID: 12229130
[TBL] [Abstract][Full Text] [Related]
26. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
Fabianowska-Majewska K; Wyczechowska D
Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
[TBL] [Abstract][Full Text] [Related]
27. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
Caron N; Lee SH; Kimball AP
Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
[TBL] [Abstract][Full Text] [Related]
28. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
[TBL] [Abstract][Full Text] [Related]
30. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia.
Dillman RO
Expert Rev Anticancer Ther; 2004 Feb; 4(1):27-36. PubMed ID: 14748654
[TBL] [Abstract][Full Text] [Related]
31. New antimetabolites in the treatment of human malignancies.
Cheson BD
Semin Oncol; 1992 Dec; 19(6):695-706. PubMed ID: 1361080
[TBL] [Abstract][Full Text] [Related]
32. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
33. Perspectives on purine analogues.
Cheson BD
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S109-16. PubMed ID: 9137964
[TBL] [Abstract][Full Text] [Related]
34. Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia.
Niitsu N; Honma Y
Leuk Lymphoma; 1999 Jul; 34(3-4):261-71. PubMed ID: 10439363
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Saven A
Semin Hematol; 1993 Oct; 30(4 Suppl 6):31-3. PubMed ID: 7908757
[No Abstract] [Full Text] [Related]
36. Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3.
Guo H; Lin SY; Ren WX; Lei Q; Chen ZC; Zhang L; Li QB
Curr Med Sci; 2018 Feb; 38(1):35-42. PubMed ID: 30074149
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with nucleoside analogs and alkylating agents.
Johnston JB; Verburg L; Shore T; Williams M; Israels LG; Begleiter A
Leukemia; 1994 Apr; 8 Suppl 1():S140-3. PubMed ID: 8152282
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
Cass CE; Selner M; Tan TH; Muhs WH; Robins MJ
Cancer Treat Rep; 1982 Feb; 66(2):317-26. PubMed ID: 6976834
[TBL] [Abstract][Full Text] [Related]
39. [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].
Ji YY; Zhang WG; Chen YX; Zhao XM; He AL; Liu J; Wang JL; Wang FX; Zhang PY; Zhang WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):213-8. PubMed ID: 20137150
[TBL] [Abstract][Full Text] [Related]
40. Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Bergmann L
Leukemia; 1997 Apr; 11 Suppl 2():S29-34. PubMed ID: 9178835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
